Phase II Study With Decitabine (5-aza-2'-Deoxycytidine, DAC) in Myelodysplastic Syndromes
OBJECTIVES: I. Determine the response of patients with myelodysplastic syndromes (including
chronic myelomonocytic leukemia) to decitabine.
OUTLINE: This is an open label, multicenter study. Patients are stratified by disease (low
risk myelodysplastic syndrome (MDS) vs. high risk MDS vs. chronic myelomonocytic leukemia).
Patients receive decitabine as a 4 hour infusion every 8 hours on days 1-3. Treatment
continues every 6-8 weeks for 4-6 courses. Patients are followed at 6 and 12 months.
PROJECTED ACCRUAL: Approximately 75 patients will be accrued for this study over 1 year.
Primary Purpose: Treatment
Stephen D. Nimer, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|
|University of Texas - MD Anderson Cancer Center||Houston, Texas 77030-4009|
|Johns Hopkins Oncology Center||Baltimore, Maryland 21287|